Main info

Identifier:

HOVON 48 NHL / NHLFIT

Sponsor:

HOVON

Included patients:

414

Active sites:

0

(of 76)

Title:

Efficacy and safety of subsequent treatment with 90Y-ibritumomab tiuxetan versus no further treatment in patients with stage III or IV follicular non-Hodgkin?s lymphoma having achieved partial or complete remission after first line chemotherapy. A prospective, multicenter, randomized phase III clinical trial.

Timeline

Flow

Details

Phase:

Prospective randomized Phase III study

Monitoring Type:

Objectives: